Main Content

“2020health is an important and thoughtful contributor to the health debate”

Dr Sarah Wollaston MP, Chairman, Health Select Committee

 
 

Drugs

Research

Various assumptions lie behind the Government's thinking on changing the way we price medicines in the UK. Changing the existing 50 year-old refined system is a risk and we need to consider the impact of VBP in other countries, the consequences of weakening NICE, the morality of the QALY and how to balance industrial and health policy.

2020health Report Value-based pricing: the wrong medicine for the nation?

Value-based pricing: the wrong medicine for the nation?

This paper tries to explore the potential impact of introducing an additional pricing scheme for new medicines on patients, who are usually blissfully unaware of pricing negotiations. It takes the approach of asking what concerns would the public still have if a new system of “value-based pricing” were introduced, despite the negotiations and new promises to include patients further in deliberations. read on Value-based pricing: the wrong medicine for the nation?

2020health Report Orphan Medicines: Special treatment required?

Orphan Medicines: Special treatment required?

This report was prompted by our concern that patients and their clinicians are not always able to access medicines for those with rare diseases. read on Orphan Medicines: Special treatment required?

2020health Report Implementing value-based pricing for pharmaceuticals in the UK

Implementing value-based pricing for pharmaceuticals in the UK

This report, in partnership with the LSE, explores value-based pricing as a new strategy for the pricing of pharmaceuticals. It details issues that need to be addressed for the new system to be effective and greater reflects the value to patients, carers, society and the economy of some new drugs which deliver health benefits that exceed NHS predictions. read on Implementing value-based pricing for pharmaceuticals in the UK